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Abstract
Background: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are essential for the cardiac
extracellular matrix (ECM) remodeling. We investigated differences in serum levels of these markers between
patients with atrial fibrillation (AF) and sinus rhythm (SR).
Methods: Serum levels of MMP-2, MMP-3, MMP-9 and TIMP-1 were measured in 86 patients: 27 on SR without any
AF history, 33 with paroxysmal and 26 with permanent AF. All subjects had essential hypertension, normal systolic
function and no coronary artery disease.
Results: Patients with AF had higher MMP-2, MMP-3 and MMP-9 and lower TIMP-1 compared to SR subjects (all p
< 0.001). Paroxysmal AF was associated with higher MMP-2 levels compared to permanent AF (p < 0.001). Matrix
metalloproteinase-9 but not MMP-3 was higher in permanent compared to paroxysmal AF group (p < 0.001).
Patients with AF had lower levels of TIMP-1 compared to those with SR while permanent AF subjects had lower
TIMP-1 levels than those with paroxysmal AF (p < 0.001 for both comparisons). Lower TIMP-1 was the only
independent factor associated with AF (OR: 0.259, 95%CI: 0.104-0.645, p = 0.004).
Conclusions: In hypertensives, paroxysmal AF and permanent AF differ with respect to serum MMPs. Increased
MMP-2 is associated with paroxysmal, whereas increased MMP-9 with permanent AF. Additionally, lower levels of
TIMP-1 had a strong association with AF incidence.
Background
Atrial fibrillation (AF) is the most common sustained
arrhythmia encountered in clinical practice, with the
highest prevalence observed among elderly people.
Atrial fibrillation is responsible for markedly increased
cardiovascular morbidity, and mortality and has been
associated with various cardiovascular disorders, predo-
minantly with hypertension, coronary artery disease,
heart failure and valvular heart disease [1]. Various fac-
tors, including atrial remodeling and inflammation, have
been implicated in the pathogenesis and perpetuation of
AF; nevertheless the exact mechanism still remains
uncertain [2-6]. Electrical remodeling is the possible
substrate for persistence of AF after the initial event
[7,8]. On the other hand, an underlying structural remo-
deling might occur before, during and after electrical
remodeling, that is only in part reversible and can addi-
tionally contribute to AF maintenance [9].
Atrial structural remodeling is strongly connected with
the fibrotic process and the subsequent disturbances in
extracellular matrix (ECM) turnover. Matrix metallopro-
teinases (MMPs), a multi-gene family of structurally and
functionally homogeneous proteolytic enzymes in bal-
ance with their tissue inhibitors (TIMPs), regulate ECM
turnover and are proposed to have a determinant role in
atrial structural remodeling involved in the development
and perpetuation of AF [10-15]. Even though, levels of
these markers have been shown to differ between AF
and sinus rhythm (SR) individuals with impaired cardiac
systolic function, there is limited knowledge regarding
* Correspondence: andkalog@gmail.com
1Department of Cardiology, Hammersmith Hospital, Imperial College
Healthcare NHS Trust, London, UK
Full list of author information is available at the end of the article
Kalogeropoulos et al. BMC Cardiovascular Disorders 2011, 11:77
http://www.biomedcentral.com/1471-2261/11/77
© 2011 Kalogeropoulos et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
similar associations among patients with AF and
patients with SR that have preserved left ventricular
(LV) systolic function and a common cardiovascular dis-
ease substrate, such as essential hypertension.
In the present study we sought to investigate whether
serum levels of MMP-2, MMP-3 and MMP-9 and their
tissue inhibitor TIMP-1 differ in hypertensive patients
with normal LV systolic function and different types of
AF compared to their SR counterparts; we also evalu-
ated associations of these markers with AF incidence
and atrial structural remodeling. The latter was inter-
preted by measuring the left atrial volume (LAV) and
LAV to body surface area (BSA) index ratio (LAV/BSA).
Methods
Study population
Before the initiation of any study procedures, a written
informed consent was obtained from each study partici-
pant. The ethics committee of our institution approved
the study, which was performed according to the princi-
ples outlined in the Declaration of Helsinki. The study
was designed to be a nested case-control study within a
prospective cohort of 175 consecutive patients with
atrial fibrillation. Of those, 59 patients with established
arterial hypertension and no other precipitated cardio-
vascular disorder or structural heart disease were
included in the case-control analysis as cases. All
patients were under anti-hypertensive treatment with
angiotensin converting enzyme inhibitors (ACEIs) or
angiotensin receptor blockers (ARBs) for at least a year
from the moment of arterial hypertension diagnosis and
none had diabetes, hyperlipidemia and a previous or
current treatment with aldosterone receptor antagonists
at the time of the study recruitment. Patients with con-
ditions associated with elevated serum concentrations of
myocardial or tissue fibrosis markers such as liver dis-
ease, renal impairment, pulmonary fibrosis and chronic
obstructive pulmonary disease, extensive wounds, meta-
bolic bone disease, malignancy, connective tissue disor-
ders, chronic or acute inflammatory disease, or recent
surgery were excluded from the study. Furthermore,
patients over 80 years old and patients with a pace-
maker/implantable cardioverter-defribrillator were also
excluded.
In order to rule out conditions potentially associated
with AF (such as coronary artery disease, heart failure,
left ventricular hypertrophy, valvular heart disease, peri-
carditis, myocarditis and various cardiomyopathies), a
standardized protocol including a detailed history, trans-
thoracic echocardiography, exercise test and any other
indicated test, was performed. The transthoracic echo-
cardiogram was carried out using Hewlett Packard
Sonos 2000 echocardiographic equipment.
Left ventricular dimensions [interventricular septal
thickness (IVSDT), posterior wall thickness (PWDT),
and LV internal diameter (LVIDD)] were measured at
the end of diastole with M-mode by using the leading-
edge to leading-edge convention. Left ventricular mass
was determined by using the ASE formula according to
the adjusted equation by Devereux et al [16]: left ventri-
cular mass (g) = 0.8[1.04(LVIDD + IVSTD + PWTD)3 -
LVIDD3] + 0.6. Left ventricular mass was divided with
the BSA area to obtain the LV mass index (LVMI). All
patients with LVMI ≥ 150 g/m2 were considered as hav-
ing LVH, according to data from the Framingham Heart
Study [17], and subsequently were excluded from our
study.
Estimation of maximal LAV was performed as follows:
from the apical four- and two-chambers view, left atrial
borders were manually traced at end-systole. The
biplane and single plane modified Simpson’s formula
was applied for maximal LAV measurement [18,19].
Images were stored in VHS magnetic tape and two inde-
pendent observers performed the final estimation of
LAV and LVMI off-line. Additionally, the LAV/BSA was
used as a complementary way of assessing left atrial
size, given that this method has been described as
superior compared to the left atrial diameter or LAV
alone in determining the existence of cardiovascular dis-
eases [20].
Laboratory methods and blood sampling
All patients of the AF group were in AF at the time of
blood sampling. Blood samples, for the measurement of
ECM turnover indices, were obtained by a peripheral
vein draw and within an hour after collection they were
centrifuged at 3,200 × g for 10 minutes at a temperature
of about 4°C. The serum was separated into aliquots and
was stored in -80°C until personnel blinded to the
patients’ clinical information performed the assay analy-
sis. Serum levels of MMP-2, MMP-3, MMP-9 (pro- and
active forms) and TIMP-1 were determined by commer-
cial standardized in vitro enzyme-linked immunosorbent
assay (ELISA) methods according to the manufacturer
instructions (RayBiotech, Inc. USA). These assays
detected only human MMPs and TIMPs with a sensitiv-
ity of < 140 pg/mL for MMP-2, < 0.3 ng/mL for MMP-
3, < 10 pg/mL for MMP-9 and < 70 pg/mL for TIMP-1.
The intra- and inter-assay coefficients of variation for all
the assays were < 10% and < 12%, respectively.
Statistical analysis
For the purposes of the analysis, the patients with AF
were sub-divided into two groups. The first group con-
sisted of subjects with symptomatic, paroxysmal AF of
recent onset defined as spontaneously or
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pharmacologically terminated AF within a maximal per-
iod of less than 72 hours from arrhythmia onset. The
latter was estimated based on patient recall of the onset
of symptoms suggestive of AF, such as palpitations,
shortness of breath and/or chest discomfort. The second
group consisted of patients with permanent AF defined
as sustained AF of more than six months in duration,
without any documented intervening periods of SR that
resisted to all attempts of SR restoration including phar-
maceutical or direct current cardioversion. Several elec-
trocardiograms that each patient underwent during their
regular basis follow up confirmed the permanent AF.
Electrocardiographic diagnosis of AF was made accord-
ing to Bellet’s definition [21]. In all AF subjects, rate
control was achieved through utilization of beta-blockers
or non-dihydropyridine calcium channel blockers and
anti-coagulation therapy was administered as indicated.
Finally, a third group of hypertensive patients with no
history of AF or any other type of atrial arrhythmias
and with the same cardiovascular profile as AF patients
was used as a control group. Control patients and AF
individuals were matched for LVMI and gender.
All quantitative variables were tested for normal distri-
bution according to the Kolmogorov - Smirnov test.
Normally distributed variables are expressed as mean
and standard deviation values, whilst non - normally
distributed data are presented as median and inter-quar-
tile range values (IQR; 25th-75th percentile). Categorical
variables were compared among the paroxysmal, perma-
nent AF and control groups using the chi-square test
for normally distributed variables and Fisher’s exact test
for non - normally distributed variables. One-way analy-
sis of variance was used to test whether these three
groups differed with respect to various continuous para-
meters of interest. A post-hoc analysis with Tukey tests
was performed to identify individual levels of signifi-
cance. If the homogeneity of variance assumption was
violated, the non-parametric Kruskal -Wallis test and
post - hoc analyses with Mann - Whitney U test were
used instead, in order to spot differences in between the
groups and individual levels of significance, respectively.
Correlations were estimated through Spearman’s rank
correlation method. Univariate logistic regression analy-
sis was performed to define factors significantly asso-
ciated with AF incidence. Because the distribution of
MMP-2, MMP-9 and TIMP-1 was skewed, logarithmic
transformation of these variables was used in the analy-
sis. Further examination of independent predictors for
AF incidence was performed, by constructing a multi-
variate logistic regression model. In the latter, all vari-
ables that had a statistical significance of p < 0.25
during univariate logistic regression analysis were
included. Values of p < 0.05 were considered statistically
significant and all tests were two tailed.
Since the nature of our research protocol was explora-
tory, formal sample size calculations were performed
with pilot data from this study. It was estimated that for
a moderate delta effect of 0.85 in the mean levels of the
measured markers within the three studied groups, a
power of 80%, and a two-tailed alpha of 0.05, a mini-
mum of 25 patients would be required for each arm of
the study. Retrospective power calculations within the
three groups revealed a high delta effect of 1.27, 1.42,
1.6 and 2.63 for MMP-2, MMP-3, MMP-9 and TIMP-9,
respectively. These effects, for a two-tailed alpha of 0.05,
corresponded to a power of more than 88.5% if more




The baseline clinical and demographic data of the study
participants are presented in Table 1. Thirty-three
patients had paroxysmal AF of recent onset, while 26
patients were in permanent AF. There were no signifi-
cant differences between the AF groups regarding age,
gender, systolic blood pressure (SBP), diastolic blood
pressure (DBP), LVMI, ejection fraction and body mass
index (BMI) (p = 0.848, p = 0.683, p = 0.717, p = 0.993,
p = 0.343, p = 0.863 p = 0.639, respectively). However,
patients with permanent AF had significantly higher
LAV and LAV/BSA than those with paroxysmal AF (p <
0.001 for both comparisons). Control subjects were
younger than patients with paroxysmal and permanent
AF (p = 0.007 and p = 0.047, respectively), but they
were comparable with regards to gender, BMI, LVMI,
SBP and DBP (p = 0.262 and p = 0.501, p = 0.210 and p
= 0.737, p = 0.859 and p = 0.988, p = 0.870 and p =
0.961, p = 0.826 and p = 0.783, respectively). In addi-
tion, patients with permanent AF had markedly
increased LAV and LAV/BSA compared to controls (p <
0.001 for both comparisons); On the other hand, sub-
jects with paroxysmal AF, had significantly higher LAV/
BSA and a tendency of higher LAV compared to con-
trols (p = 0.036, p = 0.077, respectively).
Matrix metalloproteinases and their tissue inhibitors
serum levels
Patients with permanent AF had significantly higher
serum levels of MMP-9 compared to both patients with
paroxysmal AF and controls (p < 0.001 for both com-
parisons), whereas there was no significant difference
between subjects with paroxysmal AF and those with SR
(p = 0.6) (Figure 1a). Regarding MMP-3 serum levels,
both patients with permanent and paroxysmal AF had
markedly increased MMP-3 compared to controls (p <
0.001 for both comparisons), whilst there was no differ-
ence between AF groups (p = 0.6) (Figure 1b). Patients
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Table 1 Baseline characteristics and serum levels of MMP-2, MMP-3, MMP-9 and TIMP-1 in hypertensive patients with
sinus rhythm, paroxysmal and permanent AF
Variables Sinus Rhythm (n = 27) Paroxysmal AF (n = 33) Permanent AF (n = 26) P Value
Age ± SD (years) 62.74 ± 7.20 69.51 ± 9.39 68.31 ± 8.25 0.007
Gender (Males/Females) 17/10 16/17 14/12 0.53
BMI ± SD (kg/m2) 29.78 ± 4.15 27.92 ± 4.05 28.92 ± 4.50 0.24
LVMI ± SD (g/m2) 96.10 ± 17.48 92.87 ± 19.77 95.13 ± 10.79 0.86
LA volume ± SD (mm3) 52.10 ± 13.50 63.27 ± 18.70 94.73 ± 25.14 < 0.001
LA volume/BSA ± SD (mm3/m2) 26.68 ± 7.32 33.81 ± 10.15 50.15 ± 14.43 < 0.001
LVEF (%), median (IQR) 65.0 (60.0-65.0) 62.0 (60.0-65.0) 61.0 (55.0-65.0) 0.045
SBP (mmHg), median (IQR) 132.67 ± 11.44 131.12 ± 13.446 133.54 ± 9.95 0.73
DBP (mmHg), median (IQR) 77.11 ± 5.76 78.05 ± 6.40 78.23 ± 6.07 0.77
MMP-2 (pg/ml), median (IQR) 37.00 (32.00-43.90) 206.20 (111.80-371.35) 36.23 (21.40-60.38) < 0.001
MMP-3 (ng/ml), median (IQR) 10.61 ± 4.93 18.91 ± 4.77 17.52 ± 7.01 < 0.001
MMP-9 (pg/ml), median (IQR) 86.00 (34.00-232.50) 114.25 (55.25-187.53) 368.75 (275.63-575.00) < 0.001
TIMP-1 (ng/ml), median (IQR) 3.06 (1.23-3.87) 0.58 (0.39-0.81) 0.42 (0.27-0.51) < 0.001
BMI, body mass index; LVMI, left ventricular mass index; LA, left atrium; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; DBP, diastolic blood
pressure; BSA, body surface area; SD, standard deviation; IQR, inter-quartile range
Figure 1 Serum levels of MMP-9, MMP-3, MMP-2 and TIMP-1 in hypertensive patients with Sinus Rhythm (SR), paroxysmal and
permanent AF.
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with paroxysmal AF had higher levels of MMP-2 when
compared to patients with permanent AF or controls (p
< 0.001 for both comparisons). On the other hand,
MMP-2 values were comparable between subjects with
permanent AF and controls (p = 0.625) (Figure 1c).
Patients with permanent AF had lower levels of TIMP-1
than those with paroxysmal AF (p = 0.001) and the lat-
ter had lower levels of TIMP-1 than controls (p < 0.001)
(Figure 1d).
When all AF subjects were compared to those in SR,
we observed that the latter had significantly lower
serum levels of MMP-2, MMP- 3 and MMP-9 and
higher TIMP-1 (Table 2). In addition, AF patients had
significantly lower EF; they were older and had greater
LAV and LAV/BSA than patients with SR (Table 2).
Moreover, a strong inverse correlation between LAV
and TIMP-1 levels (r = -0.396, p = 0.002) was found for
AF patients (Figure 2a), whereas a positive correlation
was noticed between LAV and MMP-9 levels (r = 0.451,
p < 0.001) (Figure 2b). Likewise, LAV/BSA was inversely
correlated with TIMP-1 (r = -0.414, p = 0.001) (Figure
2c) and positively correlated with MMP-9 (r = 0.443, p
< 0.001) (Figure 2d). There were no significant correla-
tions between the measured ECM turnover markers and
ejection fraction, LVMI, age, systolic and diastolic blood
pressure.
Univariate analysis showed that lower logTIMP-1 was
the strongest factor associated with AF incidence (OR:
0.257, 95%CI: 0.134-0.493, p < 0.001). Additional factors
that were significantly associated with AF were MMP-3
levels (OR: 1.050, 95%CI: 1.015-1.086, p = 0.005); LAV
(OR: 1.011, 95%CI: 1.002-1.020, p = 0.02); LAV/BSA
(OR: 1.020, 95%CI: 1.004-1.036, p = 0.016). Further mul-
tivariate analysis adjusted for age, MMP-3, logMMP2,
logMMP-9, ejection fraction, LAV and LAV/BSA
showed that lower serum logTIMP-1 was the only inde-
pendent factor associated with AF incidence (OR: 0.259,
95%CI: 0.104-0.645, p = 0.004), (Figure 3).
Discussion
The transition of paroxysmal to persistent and even-
tually to permanent AF is a multi-factorial process. As
implicated by the concept of “AF begets AF”, AF per se
forms the conditions for its relapse, persistence and per-
petuation [7]. When arrhythmia becomes persistent, it is
then associated with atrial enlargement and microscopic
structural changes, both consisting of the main features
of atrial structural remodeling [22,23]. Both the irregular
ECM turnover and the fibrotic process are suggested to
be important components of the latter [9,24-29].
The composition of ECM, which predominantly con-
sists of collagen types I and III, fibril, fibronectin and
laminin, is under the strict control of MMPs that are
responsible for the degradation of all the matrix compo-
nents between cells [30]. In addition, the TIMPs also
play a significant role in this pathophysiological pathway
by inhibiting the proteolytic activity of MMPs and both
of them appear to be in a delicate balance [30].
Recently, it has been demonstrated that qualitative and
quantitative changes in relevant ECM proteins and their
regulatory molecules, might comprise a potent mechan-
ism of AF. In particular, a study by Mukherjee et al.
showed chamber specific differences of collagen content,
MMPs and TIMPs levels in patients with heart failure
and AF versus those in SR, suggesting a potential role
for these molecules in the control of ECM remodeling
in heart failure subjects with AF [12]. In their study,
levels of MMP-1 in the right atrium, MMP-9 in the left
atrium and TIMP-3 in the right ventricle, left atrium
and left ventricle were greater with AF, whereas TIMP-1
Table 2 Baseline characteristics and serum levels of MMP-2, MMP-3, MMP-9 and TIMP-1 in the total cohort of AF
patients and individuals with sinus rhythm
Variables Sinus Rhythm (n = 27) AF (n = 59) P Value
Age ± SD (years) 62.74 ± 7.20 68.98 ± 8.85 0.002
Gender (Males/Females) 17/10 30/29 0.295
BMI ± SD (kg/m2) 29.78 ± 4.15 28.36 ± 4.24 0.15
LVMI ± SD (g/m2) 96.10 ± 17.48 93.89 ± 16.14 0.65
LA volume ± SD (mm3) 52.10 ± 13.50 77.13 ± 26.71 < 0.001
LA volume/BSA ± SD (mm3/m2) 26.68 ± 7.32 41.01 ± 14.62 < 0.001
LVEF (%), median (IQR) 65.0 (60.0-65.0) 62.0 (60.0-65) 0.02
SBP (mmHg), median (IQR) 132.67 ± 11.44 132.19 ± 11.99 0.47
DBP (mmHg), median (IQR) 77.11 ± 5.76 78.13 ± 6.20 0.86
MMP-2 (pg/ml), median (IQR) 37.00 (32.00-43.90) 114.80 (37.20-338.35) 0.001
MMP-3 (ng/ml), median (IQR) 10.61 ± 4.93 18.30 ± 5.85 < 0.001
MMP-9 (pg/ml), median (IQR) 86.00 (34.00-232.50) 189.40 (95.90-361.90) 0.011
TIMP-1 (ng/ml), median (IQR) 3.06 (1.23-3.87) 0.47 (0.36-0.73) < 0.001
BMI, body mass index; LVMI, left ventricular mass index; LA, left atrium; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; DBP, diastolic blood
pressure; BSA, body surface area; SD, standard deviation; IQR, inter-quartile range
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levels were higher in the right ventricle of AF subjects.
Furthermore, Xu et al showed that in the atria of
patients with AF and end-stage heart failure there was
increased deposition of collagen type I that was signifi-
cantly associated with down-regulation of TIMP-2 and
up-regulation of the activity and expression of MMP-2
[14]. These structural disturbances were subsequently
associated with increased atrial dimensions and higher
odds of AF recurrence [14]. Accordingly, patients with
AF and relatively preserved LV systolic function had
higher (as higher as the duration of AF was) activity of
MMP-2 and MMP-9 and lower expression of TIMP-1.
This deregulation was related to a considerably
increased atrial fibrosis [15].
The results presented herein strengthen the aforemen-
tioned findings. In particular, we clearly demonstrated
that lower serum TIMP-1 is the most powerful indepen-
dent factor associated with higher AF incidence in
patients with essential hypertension and normal left ven-
tricular systolic function. Additionally, lower levels of
TIMP-1 were strongly related to AF maintenance, whilst
even though higher levels of MMPs - especially MMP-9
and MMP-3- were not an independent predictor of AF
incidence, they were significantly increased in subjects
with permanent AF. It appears that increased levels of
MMPs with concomitant reduction of TIMP-1 may
endorse atrial dilatation and AF persistence through the
augmented breakdown of ECM [10]. On the other hand,
this imbalance in favor of MMPs expression may be a
part of a quite complex equation that might be related
to collagen degradation products that are in a position
to stimulate the development of a defectively structured
Figure 2 Scatter dot diagrams, of all AF patients taken together, demonstrating direct linear correlations between: a. left atrial volume
and logMMP-9; b. left atrial volume and logTIMP-1; c. left atrial volume to BSA ratio and logMMP-9; d. left atrial volume to BSA ratio and
logTIMP-1.
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fibrotic tissue [31]. Accordingly, our data demonstrated
that increased MMP-9 and lower TIMP-1, were strapp-
ingly associated with increased left atrial remodeling as
this was interpreted by LAV and LAV/BSA assessment.
The exact mechanism behind the increase of MMP-9 in
patients with fibrillating atria is unclear. Previous studies
have shown that an ACE-dependent increase in the
amount of activated extracellular signal-regulated
kinases Erk1/Erk2 in atrial interstitial cells might stimu-
late the fibrotic process in atria with AF [32]. Angioten-
sin II has been implicated in the up-regulation of the
MMP-9 and it has been showed that the former is asso-
ciated with the cardiac hypertrophy process and cardiac
remodeling [33]. It was also reported that angiotensin II
is involved in the mechanism of the atrial electrical
remodeling, and its blockade may lead to a better thera-
peutic management of AF [34]. Consequently, altera-
tions in the renin-angiotensin system in AF subjects
could substantiate a subsequent deregulation of MMPs
secretion. In our study, however, all the participants
were in anti-hypertensive treatment with ACE inhibitors
or ARBs, suggesting that other additional mechanisms
could trigger MMP-9 expression. Indeed, it has been
shown that factors strongly associated with AF persis-
tence involving inflammatory cytokines, increased trans-
mural stretch and transforming growth factor beta-1 are
potent inducers of MMPs expression including MMP-9
[35,36]
In contrast to the aforementioned results, others
showed that in patients with AF, increased collagen
deposition was associated with increased TIMPs to
MMPs ratio [11]. This paradox was also the case in
experimental studies with rapid atrial pacing induced
AF, wherein increased MMP-9 expression was accompa-
nied by an incremental tendency of TIMP-1 and -3 as
well [37]. In addition, a recent study involving patients
with lone AF revealed that individuals with persistent
AF had higher serum levels of C-terminal pro-peptide of
collagen type-I and TIMP-1 and lower levels of MMP-1
when compared to normal individuals [38]. These
inconsistent results are quite intriguing and can be
explained in part by the significant differences regarding
the methodology of each study. In the first one, a model
of rapid atrial pacing in pigs was used, demonstrating
similar electrophysiological properties with human AF
such as multiple re-entrant wavelets [39]. However, such
experimental models do not relate closely to the most
frequent clinical conditions associated with AF such as
the cardiovascular disease substrate and consequential
implications involving atrial dilatation, fibrosis and con-
duction slowing [40,41]. In the second study, a comple-
tely different cohort of patients with paroxysmal and
Figure 3 The likelihood of AF incidence according to logTIMP-1 serum levels in patients with essential hypertension.
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persistent “lone” AF was used. Compared to our study
population, these patients had notably higher levels of
TIMP-1, were younger and had lower ejection fraction.
The aging, the cardiovascular disease substrate and the
functional capacity of the heart are factors that could be
associated with ECM turnover and could affect the
levels of proteins that regulate the latter. In our study,
essential hypertension, properly treated with ACEIs or
ARBs, was the underlying disorder for AF. Arterial
hypertension or other heart disorders could have signifi-
cant effects on the proteins that regulate ECM turnover
and consequently the latter may have a diverse profile,
strongly related to the precipitating cardiac diseases.
Another interesting finding of our study was the
remarkably increased serum MMP-2 of patients with
paroxysmal AF of recent onset compared to both, indi-
viduals with SR and those with permanent AF. It
becomes evident that MMP-2 emerges as an acute reac-
tant in recent onset AF. In fact, recent data [42-44]
demonstrated that except for the extracellular activity of
MMP-2 that occurs mainly on a “days to week” time
scale, there is an acute MMP-2 up-regulation ("minutes
to hours” time-scale) mediating the initial cellular
response to enhanced oxidative stress. The latter
appears to be associated with non-ECM protein targets.
In particular, contrary to previous thoughts, MMP-2 has
the capacity of myocardial intracellular expression,
which can be actively up-regulated in response to sev-
eral factors that have been involved in paroxysmal AF
pathophysiology, including hypoxia, angiotensin II,
endothelin-1 or pro-inflammatory cytokines [42,45,46].
In support of this, others showed that MMP-2, which is
localized to the thin cardiac myofilaments, is implicated
in myocardial stunning and ensuing contractile dysfunc-
tion during early ischemia/reperfusion injury through
degradation of troponin I (TnI) and myosin light chain-
1 [43,44]. Moreover, it has been observed that MMP-2
inhibitors may reduce TnI degradation in the myocar-
dium after ischemia reperfusion injury process [43]. It
could be considered, therefore, that MMP-2 can emerge
as a molecule that can act on a far quicker time-scale in
response to subtle cellular changes like those during
initial stages of AF and contribute to early atrial stun-
ning and contractile remodeling.
Study limitations
Our results should be ideally confirmed by examination
of additional markers of fibrosis, ECM remodeling and
oxidative stress in tissue samples. For example, the addi-
tional assessment of the oxidative stress by measuring
the serum levels of a marker like malondialdehyde
would also add supplementary information with respect
to the higher MMP-2 levels in patients with paroxysmal
AF. Additionally, the immunoassay approach utilized in
the present study could not differentiate the pro-form
and active form of the MMP subtypes. Nonetheless, our
principal purpose was not to examine the effect of
MMPs to the fibrillating atria but rather to reveal any
potential associations of different types of AF with spe-
cific MMPs patterns. Indeed, our findings showed a
strong relation of AF with MMPs and that different sub-
types of the latter could be associated with the different
types of AF. Moreover, supplementary measurement of
ECM turnover markers in several time intervals after
the AF initiation could add significant information
regarding their tendency throughout the initial stages of
AF. However, the enrollment of AF patients with: essen-
tial hypertension as the only cardiovascular disease sub-
strate; no echocardiographic evidence of structural heart
disease (left ventricular hypertrophy); similar profile
regarding the treatment of hypertension and our inten-
sive efforts to exclude other factors associated with
ECM remodeling contributed significantly to the relia-
bility of our findings.
Due to insufficient data we could not further adjust
for time since the first diagnosis of hypertension and
time on anti-hypertensives, factors, that could have
enhance our insight in the role of hypertension and
structural heart effects and the associations with some
of the observed changes in MMPs and TIMP-1. Addi-
tionally, even though we rigorously tried to match our
study groups (AF and controls) with respect to all the
referred demographic data, AF subjects were older than
controls. However, paroxysmal and permanent AF
groups were comparable for age and differed signifi-
cantly with regards to MMP-2, MMP-9 and TIMP-1
levels. Additionally, there were no associations between
age and ECM turnover makers in AF individuals, sug-
gesting that age did not affect the interpretation of our
results.
Conclusions
In conclusion, we present data on serum TIMP-1 and
MMPs levels in specific subsets of hypertensive patients
with AF and SR. Lower serum levels of TIMP-1 were
associated with increased AF incidence, whereas higher
serum levels of MMP-3, MMP-9 and lower levels of
TIMP-1 were strongly associated with permanent AF.
Additionally, increased MMP-9 and lower TIMP-1 in
patients with permanent AF were associated with higher
states of atrial remodeling as this was assessed by LAV
and LAV/BSA ratio, suggesting that the imbalance of
TIMP-1 and MMP-9 could intensify atrial remodeling
and subsequently lead to maintenance of AF. Finally,
patients with AF of recent onset depicted markedly
increased serum MMP-2 compared to both, control sub-
jects and patients with permanent AF signifying a new
potential role of MMP-2 as an acute reactant that might
Kalogeropoulos et al. BMC Cardiovascular Disorders 2011, 11:77
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be linked with atrial dysfunction during the initial stages
of AF.
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